Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-02-28
2006-02-28
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093200, C424S450000
Reexamination Certificate
active
07005424
ABSTRACT:
The present invention relates to methods for the inhibition, of the gene product of the neu oncogene, p185neu tyrosine kinase. Over-expression of the neu oncogene leads to chemoresistance. The methods disclosed involve the novel use of E1A and/or LT in combination with chemotherapeutic drugs to treat carcinoma. Furthermore, E1A surprisingly potentiates the antineoplastic effects of the chemotherapeutic agents. The inventors propose that E1A sensitizes cancer cells such that they become amenable to treatment by chemotherapeutic drugs.
REFERENCES:
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 5641484 (1997-06-01), Hung et al.
patent: 5643567 (1997-07-01), Hung et al.
patent: 5651964 (1997-07-01), Hung et al.
patent: 5776743 (1998-07-01), Frisch
patent: 5814315 (1998-09-01), Hung et al.
patent: 6197754 (2001-03-01), Hung et al.
patent: 6271207 (2001-08-01), Cristiano et al.
patent: 6326356 (2001-12-01), Hung et al.
patent: 6395712 (2002-05-01), Hung et al.
patent: 6683059 (2004-01-01), Hung et al.
patent: WO 90/08759 (1990-08-01), None
patent: WO 90/15595 (1990-12-01), None
patent: WO 92/10573 (1992-06-01), None
patent: WO 93/03769 (1993-03-01), None
patent: WO 94/21115 (1994-09-01), None
patent: WO 95/13813 (1995-05-01), None
patent: WO 95/16051 (1995-06-01), None
Powles et al. A Randomised Trial Comparing Combination Chemotherapy Using Mitomycin C, Mitozantrone and Methotrexate (3M) with Vincristine, Anthracylcline and Cyclophosphamide (VAC) In Advanced Breast Cancer. Brit. J. Cancer, 1991, vol. 64, pp. 406-410.
Larsson et al. Cytotoxic Activity of Topoisomerase II Inhibitors in Primary Cultures of Tumor Cells from Patients with Human Hematologic and Solid Tumors. Cancer. 1994, vol. 74, pp. 2857-2862.
Culine et al. Long-Term Results of Two VAB-Like Regimes in Malignant Germ Cell Tumours of the Ovary. Eur. J. Cancer. 1994, 30A, pp. 1239-1244.
Norton, L. Salvage Chemotherapy of Breast Cancer. Seminars in Oncol. 1994, vol. 21, pp. 19-24.
Akiyama et al., “Genistein, a Specific Inhibitor of Tyrosine-Specific Protein Kinases,”J. Biol. Chem., 262(12):5592-5595, 1987.
Bacus et al., Differentiation of cultured human breast cancer cells (AU-565) and MCF-7) associated with loss of cell surfaceHER-2
euantigen.Mol. Carcinog., 3:350-362, 1990.
Bacus, et al., Tumor-inhibitory monoclonal antibodies to theHER-2
eureceptor induce differentiation of human breast cancer cells.Cancer Res. 52: 2580-2589, 1992.
Bargmann & Weinberg, “Increased Tyrosine Kinase Activity Associated with the Protein Encoded by the Activated Neu Oncogene, ”Proc. Natl. Acad. Sci. USA, 85:5394-5398, 1988.
Bargmann et al., “Multiple Independent Activations of the neu Oncogene by a Point Mutation Altering the Transmembrane Domain of p185,”Cell, 45:649-657, 1986.
Bargmann et al., “The neu Oncogene Encodes an Epidermal Growth Factor Receptor-Related Protein,”Nature, 319:226-230, 1986.
Berk and Sharp, “Structure of the Adenovirus 2 Early mRNAs,”Cell, 14:695-711, 1978.
Berk, “Adenovirus Promoters and EIA Transactivation,”Ann. Rev. Genet., 20:45-79, 1986.
Bishop JM “The molecular genetics of cancer,”Science, 235 (4786), p305-11, 1987.
Brader et al., “Adenovirus E1 A Expression Enhances the Sensitivity of an Ovarian Cancer Line to Multiple Cytotoxic Agents Through an Apoptotic Mechanisms,” Proceedings of the American Association for Cancer Research, 37:30, 1996. (abstract).
Brunet et al., “Concentration Dependence of Transcriptional Transactivation in Inducible E1A-Containing Human Cells,”Mol. Cell. Bio., 8(11):4799-4807 (1988).
Buchman et al., Appendix A: The SV40 Nucleotide Sequence,DNA Tumor Viruses, 799-813.
Chan et al., “Selective inhibition of the growth of ras-transformed human bronchial epithelial cells by emodin, a protein-tyrosine inhibitor,”Biochem. Biophys. Res. Commun., 193:1152-1158, 1993.
Chang, et al., “Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease,”Seminars in Oncology, 22(3, Supp.6):124-127, 1995.
Chevalier, Fumoleau, Kerbrat, Dieras, Roche, Krakowski, Azli, Bayssas, Lentz, Van Glabbeke, “Decetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer,”J. Clin. Oncol., 13:314-322, 1995.
Coussens et al., “Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene,”Science, 230:1132-1139, 1985.
Douglas et al., “Modulation of transformation of primary epithelial cells by the second exon of the Ad55 E1A12S gene,”Oncogene, 6:2093-2103, 1991.
Downward et al., “Close Similarity of Epidermal Growth Factor Receptor and v-erb-B Oncogene Protein Sequences,”Nature, 307:521-527, 1984.
Egan et al., “Transformation by Oncogenes Encoding Protein Kinases Induces the Metastatic Phenotype,”Science, 238:202-205, 1987.
Felgner et al., “Gene Therapeutics: The Direct Delivery of Purified Genes in vivo and Their Application as Drugs, Without the Use of Retroviruses, Is Discussed,”Nature, 349:351-352 (1991).
Felgner, P.L., and Ringold, G.M., Cationic liposome-mediated transfection,Nature, 337:387-388, 1989.
Figge et al., “Prediction of Similar Transforming Regions in Simian Virus 40 Large T, Adenovirus E1A, and myc Oncoproteins,”Journal of Virology, 62:(5)1814-1818, 1988.
Freedman and Shin, “Use of Nude Mice for Studies on the Tumorigenicity of Animal Cells,”The Nude Mouse in Experimental and Clinical Research, 1978.
Friche et al., “Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [eH]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells,”Br. J. Cancer, 67(2):226-231, 1993.
Frisch et al., “Adenovirus E1A Represses Protease Expression and Inhibits Metastasis of Human Tumor Cells,”Oncogene, 5:75-83 (1990).
Fung et al., “Activation of the Cellular Oncogene c-erbB by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis Virus”,Cell, 33:357-368, 1983.
Gazit et al., “Chemo-adoptive immunotherapy of nude nice implanted with human colorectal carcinoma and melanoma cell lines,”Cancer Immunology Immunotherapy, 35:135-144, 1992.
Giovanella, Stehlin, Shepard, Williams, “Correlation between response to chemotherapy of human tumors in patients and in nude mice,”Cancer, 52:1146-1152, 1982.
Goo, X., and Huang, L., A Novel Cationic Liposome Reagent for Efficient Transfection of Mammalian Cells,Biochemical and Biophysical Research Communication, 179:(1)280-285, 1991.
Haley et al., “Transformation Properties of Type 5 Adenovirus Mutants that Differentially Express the E1A Gene Products,”Proc. Natl. Acad. Sci. USA, 81:5734-5738, 1984.
Harlow et al., “Monoclonal Antibodies Specific for Adenovirus Early Region 1A Proteins: Extensive Heterogeneity in Early Region IA Products,”J. of Virology, 55(3):533-546 (1985).
Hearing et al., “Sequence-Independent Autoregulation of the Adenovirus Type 5 E1A Transcription Unit,”Mol. Cell. Bio., 5(11):3214-3221 (1985).
Houweling et al., “Partial Transformation of Primary Rat Cells by the Leftmost 4.5% Fragment of Adenovirus 5 DNA,”J. Virology, 105:537-550, 1980.
Hudziak et al., “Amplified Expression of the HER2/ERBB2 Oncogene Induces Resistance to Tumor Necrosis Factor a in NIH 3T3 Cells,”Proc. Natl. Acad. Sci. USA, 85:5102-5106, 1988.
Hudziak et al., “Increased expression of the putative growth factor p 185 j2causes transformation and tumorigenesis of NIH 3T3 cells,”Proc. Natl. Acad. Sci. USA, 84:7159-7163, 1987.
Hung et al., “Amplification of the proto-neu oncogene facilitates oncogenic activation by a sing
Hung Mien-Chie
Ueno Naoto T.
Board of Regents , The University of Texas System
Crouch Deborah
Fulbright & Jaworski L.L.P.
LandOfFree
Nucleic acid encoding an E1A gene product sensitizes... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acid encoding an E1A gene product sensitizes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acid encoding an E1A gene product sensitizes... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3688748